. CpG-DNA protects mice from S. aureus MW2 infection. (A) Schematic diagram of the experimental process. BALB/c mice were administered CpG-DNA 1826 via an i.p. injection (2.5 mg/kg mouse). After 7 days, the mice were i.v. injected with S. aureus MW2 (1 × 10 7 CFU). (B) Survival of the mice was recorded for 7 days after S. aureus MW2 infection. The percentage of surviving mice in each treatment group is shown (n = 10/ group). (C) Two days after S. aureus MW2 infection, the mice were sacrificed, and the indicated tissues were removed and homogenized in PBS. The homogenates (n = 5/group) were diluted and plated on agar plates to measure S. aureus MW2 colony forming units (CFU). (D) Histopathology of the indicated tissues two days after infection. Scale bar, 10 μm. 1826, CpG-DNA 1826; MW2, S. aureus MW2. The results presented are representative of three independent experiments. ***p < 0.0005.
Scientific REPORTs | (2018) 8:16236 | DOI:10.1038/s41598-018-34722-y colony forming units (CFU)), and survival rates were monitored for 7 days. Compared to the mice that only received S. aureus MW2, the survival rate of the mice pre-treated with CpG-DNA prior to S. aureus MW2 infection was 50% greater (10% vs 60%, Fig. 1B ). Two days after S. aureus MW2 infection, the lungs, kidney, and spleen were excised to assess bacterial burden. All of the tissues tested were infected by bacteria, with the highest CFU detected in the kidney. However, the tissue bacterial loads were all decreased by CpG-DNA 1826 pre-treatment (Fig. 1C ). Next, the histopathology of each tissue was examined. Abscesses were observed in the kidneys after bacterial infection; however, no abscesses were detected when the mice were pre-treated with CpG-DNA 1826 before infection (Fig. 1D ). Therefore, these results suggest that the prophylactic injection of CpG-DNA into the peritoneal cavity increased survival and enhanced bacterial clearance in mice subsequently infected with S. aureus MW2.
CpG-DNA protects and modulates cell populations in the peritoneal cavity, spleen, and bone marrow. To investigate the mechanisms underlying the apparent protective effects of CpG-DNA pre-treatment against S. aureus MW2 infection, we analyzed cell populations in the peritoneal cavity, spleen, and bone marrow and found that lymphoid (B and T cells) and myeloid cells (macrophages, dendritic cells, and neutrophils) were altered by CpG-DNA pre-treatment and S. aureus MW2 infection in the different tissues (Fig. 2) .
In the peritoneal cavity, the ratio of myeloid and lymphoid cells was reversed by CpG-DNA treatment ( Fig. 2A) . The myeloid cell population in the peritoneal cavity was decreased by CpG-DNA administration (61% compared to the PBS control), whereas the population of lymphoid cells was increased (160% compared to the PBS control). The myeloid cell population was primarily comprised of F4/80 + CD11b + macrophages. Although the population of F4/80 − CD11c + dendritic cells was very small, CpG-DNA administration caused a 3-fold increase in the cell number compared to the PBS control. In the case of the lymphoid cells, the increase in the T cell population, including CD4 + and CD8 + T cells, was marked (4.6-fold compared to the PBS control). As well, similar increases were observed in the total number of B cells. A detailed analysis of the B cell population revealed that B1 (CD23 − ) cells were decreased and B2 (CD23 + ) cells were slightly increased following CpG-DNA treatment. Following infection with S. aureus MW2, all of the cells markedly decreased except neutrophils, but pre-treatment with CpG-DNA resulted in cell populations that were similar to the untreated control, despite lower total cell numbers ( Fig. 2A ).
In the bone marrow, the population of myeloid cells increased (150% compared to the PBS control), whereas the lymphoid cell population decreased (65% compared to the PBS control) in response to CpG-DNA ( Fig. 2B) . Further, the population of myeloid cells was primarily comprised of F4/80 − Gr-1 + neutrophils. The majority of the lymphoid cells were B cells, especially B1 cells. In contrast to the peritoneal cavity, the ratio of B1 and B2 cells was not changed by CpG-DNA treatment. S. aureus MW2 infection induced a marked decrease in all of the cell populations, but the decreases were prevented by pre-treatment with CpG-DNA ( Fig. 2B ).
In the spleen, CpG-DNA administration did not induce any significant changes in the cell populations ( Fig. 2C ). However, a decrease in lymphoid cells was observed (60% compared to the PBS control) following infection with S. aureus MW2. When the mice were pre-treated with CpG-DNA before bacterial infection, the number of lymphoid cells was greater than the PBS control. Compared to S. aureus MW2 infection alone, pre-treatment with CpG-DNA resulted in greater than 2-fold increases in both lymphoid and myeloid cells ( Fig. 2C ).
Based on these results, we concluded that S. aureus MW2 infection induces decreases in the total numbers of myeloid and lymphoid cells in the peritoneal cavity, bone marrow, and spleen. However, pretreating the mice with CpG-DNA generally prevented the apparent decreases in immune cells following infection. This phenomenon suggests that the observed cell numbers following CpG-DNA treatment may be related to the mouse survival rates. Most importantly, CpG-DNA treatment shifted the population of immune cells in the peritoneal cavity toward increased macrophages and adaptive immune cells such as B2 and T cells ( Fig. 2A ). Therefore, we propose that the cells in the peritoneal cavity may be the primary regulator of the antibacterial effects of CpG-DNA in our experimental system.
Antibodies binding to bacteria are generated by CpG-DNA injection in vivo and in vitro.
Because the administration of CpG-DNA triggered B cell proliferation and differentiation and the production of T cell-independent polyclonal antibodies 7 , we examined the IgG titer in the peritoneal fluid and serum at various time points after i.p. injection of CpG-DNA 1826 to confirm antibody production. Based on our observation that the injection of CpG-DNA enhanced survival against S. aureus MW2 infection, we believed it was likely that some bacteria-reactive antibodies could be induced by the injection of CpG-DNA 1826 in the peritoneal cavity. We harvested peritoneal fluid and serum from mice following the i.p. injection of CpG-DNA 1826 and i.v. infection with S. aureus MW2 ( Fig. 1A) and measured total levels of IgG and IgG isotypes reactive to S. aureus MW2 using plates coated with S. aureus MW2. CpG-DNA alone induced a drastic increase in reactive total IgG in the peritoneal fluid, but there was comparatively small change in the sera. Infection with S. aureus MW2 caused a decrease in the production of reactive IgG both in the peritoneal fluid and serum. However, pre-administration of CpG-DNA 1826 prior to bacterial infection induced a significantly increased production of reactive IgG. The IgG3 isotype was the most abundant and the amount of S. aureus MW2-reactive IgG3 isotype was significantly increased in the CpG-DNA-treated group (Fig. 3A,B) .
To further investigate the antibodies induced by CpG-DNA administration, the mice received an i.p. injection of PBS or CpG-DNA 1826 and the peritoneal fluid and serum were analyzed after 7 days. To determine if the CpG-DNA-induced IgG could bind various Gram-positive bacterial species, we performed an ELISA assay using plates coated with S. aureus, S. aureus MW2, S. epidermidis, and S. pyogenes. The ELISA results indicated that the levels of each bacteria-reactive IgG were increased in the peritoneal cavity and sera following the injection of CpG-DNA 1826 ( Fig. 3C,D) . To determine if treatment with CpG-DNA activated the TLR9 signaling pathway to produce bacteria-reactive antibodies, the same experiments were performed using BALB/c TLR9 −/− mice. No Scientific REPORTs | (2018) 8:16236 | DOI:10.1038/s41598-018-34722-y significant changes in the levels of bacteria-reactive antibodies were detected in the peritoneal fluid or sera of TLR9 −/− mice following the injection of CpG-DNA 1826 ( Fig. 3E,F) . Therefore, these data suggest that CpG-DNA induced the production of bacteria-reactive antibodies through the TLR9 signaling pathway. To determine whether bacteria-reactive antibodies could be induced in vitro by CpG-DNA, immune cells were harvested from the peritoneal cavity of the mice, stimulated in vitro with CpG-DNA 1826 and non-CpG-DNA 2041, and the antibody levels were measured in the cell culture supernatants. As shown in Fig. 4A , general IgG production was significantly increased in response to CpG-DNA 1826 compared to PBS control or non-CpG-DNA 2041. When the mice were first primed with CpG-DNA in vivo and the peritoneal cavity cells were stimulated in vitro, basal IgG production was enhanced, but the added effect of CpG-DNA treatment was very weak (Fig. 4A ). To determine the binding capability of the antibodies secreted from the in vitro-cultured peritoneal cells, we measured bacteria-reactive IgG levels using plates coated with the four Gram-positive bacteria species. Bacteria-reactive IgG was significantly increased in response to CpG-DNA, but the reactive antibody levels detected in response to PBS or non-CpG-DNA were very low ( Fig. 4B ). Generally, antibody production is associated with the presence of mature B cells, such as plasma B cells. To investigate which B cells were secreting bacteria-reactive antibodies in response to CpG-DNA, an i.p. injection of CpG-DNA 1826 was administered to the mice. Nine days after the injection of CpG-DNA 1826, we harvested immune cells from the peritoneal cavities of the mice, sorted CD23 − CD19 + B cells (B1 cells) and CD23 + CD19 + cells (B2 cells) from peritoneal lymphocytes ( Fig. 4C ) and stimulated the cells with CpG-DNA 1826 in vitro. Both the B1 and B2 cells secreted increased amounts of IgG in response to CpG-DNA stimulation (Fig. 4D ). However, the IgG levels produced by B cells in vitro were decreased when the mice were pre-treated with CpG-DNA prior to the isolation of the peritoneal cavity cells, suggesting that the CpG-DNA modulated B cell activity ( Fig. 4D ). Assays of each bacteria-reactive IgG, measured using Gram-positive bacteria-coated plates, suggested that the production of bacteria-reactive IgG was increased by CpG-DNA stimulation in vitro and that priming with CpG-DNA in vivo modulated antibody production ( Fig. 4E ). Taken together, these results indicate that both B1 Bacteria-reactive antibodies in the peritoneal cavity induced by CpG-DNA enhance phagocytosis. We examined whether bacteria-reactive antibodies induced by CpG-DNA in the peritoneal cavity could enhance phagocytosis and consequently inhibit bacterial infection. We purified the polyclonal antibodies from the peritoneal fluid of PBS-injected mice ( Fig. 5A ) and CpG-DNA 1826-injected mice (Fig. 5B ). The total amounts of IgG in the peritoneal cavity were increased approximately 2.5-fold by CpG-DNA 1826 administration compared to the PBS controls (7.5 μg/mouse versus 3 μg/mouse). The ability of the antibodies to bind S. aureus MW2 was also measured by ELISA. The results revealed increased binding of the antibodies induced by the administration of CpG-DNA 1826 to S. aureus MW2 than the antibodies from the PBS-injected mice (Fig. 5C ). Next, we investigated the phagocytic capacity of these antibodies. Fluorescein isothiocyanate (FITC)-labeled S. aureus MW2 was incubated with the purified antibodies and a phagocytosis assay was performed by confocal microscopy using RAW 264.7 mouse macrophage cells (Fig. 5D,E) . The phagocytic index was increased in the presence of the antibodies.
Antibacterial effect of the bacteria-reactive monoclonal antibody. Based on our results, we believed that activated B cell clones induced by CpG-DNA might secrete antibodies harboring antibacterial activity, and that the antibodies might enhance phagocytosis via macrophages, dendritic cells, and neutrophils from the peritoneal cavity. To construct the B cell clone secreting bacteria-reactive antibodies induced by CpG-DNA, the mice were i.p. injected with CpG-DNA 1826. After 7 days, the peritoneal cells were harvested and fused with SP2/0 myeloma cells. We isolated the hybridoma clone, termed 3F5H6, which was secreting a monoclonal antibody reactive to S. aureus MW2. The monoclonal antibody (3F5H6 mIgG) purified from ascites was analyzed by SDS-PAGE (Fig. 6A ). The 3F5H6 mIgG isotype was IgG2b (Fig. 6B) , and the ability of 3F5H6 mIgG to bind several Gram-positive bacteria was confirmed by ELISA ( Fig. 6C ). Because IgG can non-specifically bind to S. aureus through Protein A, the same experiments were performed using a S. aureus Protein A deletion mutant (S. aureus Δspa). Normal IgG and 3F5H6 mIgG were reactive to S. aureus Δspa, suggesting that the binding of normal IgG and 3F5H6 mIgG to S. aureus MW2 was specific ( Supplementary Fig. S1 ).
To examine the effect of 3F5H6 mIgG on RAW 264.7 cell-mediated phagocytosis, FITC-labeled S. aureus MW2 was incubated with PBS, normal mouse IgG, or 3F5H6 mIgG (Fig. 6D,E) . We also investigated the effect of 3F5H6 mIgG on mouse peritoneal cavity cell-mediated phagocytosis (Fig. 6F,G) . The results indicated that the phagocytic activity of RAW264.7 cells and mouse peritoneal cavity cells was increased in the presence of 3F5H6 mIgG compared to normal mouse IgG (1.5-1.8 fold). To directly investigate the in vivo phagocytic effect of antibodies, the mice were administered an i.p. injection of normal mouse IgG or 3F5H6 mIgG pre-incubated with FITC-labeled S. aureus MW2 cells. We then analyzed the phagocytic level by flow cytometry (Fig. 6H,I) . Both the normal IgG and 3F5H6 mIgG enhanced the phagocytosis of macrophages ( Fig. 6H ) and dendritic cells (Fig. 6I ) in the peritoneal cavity with higher effect by 3F5H6 mIgG than the normal IgG. These results suggested that 3F5H6 mIgG functions as an effective phagocytic mediator in mouse peritoneal cells and that phagocytic immune cells are involved in the antibacterial effect of CpG-induced antibodies.
Therapeutic effects of the bacteria-reactive monoclonal antibody against S. aureus MW2 infection.
To confirm the antibacterial effects of 3F5H6 mIgG against S. aureus MW2 infection, BALB/c mice were infected with S. aureus MW2, administered an i.v. injection of PBS, normal IgG, or 3F5H6 mIgG, and then mortality, infection in tissues, and histopathology were observed according to the experimental schedule (Fig. 7A) . All of the mice infected with S. aureus MW2 that did not receive antibody died 5 days after infection, but 30% of the normal IgG injected mice and 70% of 3F5H6 IgG injected mice survived until 7 days after infection (Fig. 7B) . To investigate S. aureus MW2 infection in specific tissues, the lungs, kidneys, and spleen were prepared 2 days after infection and a CFU assay was performed. We observed decreased bacterial loads in the tissues, especially in the kidneys, from the mice administered the 3F5H6 mIgG (Fig. 7C) . The histopathology of the tissues was also evaluated 2 days after infection. Bacterial burdens were only found in the kidney, and smaller bacterial burdens were detected in antibody-injected-mice compared to mice only infected with S. aureus MW2 (Fig. 7D ). Thirty days after S. aureus MW2 infection, we examined the histopathology of the lungs, kidneys, and spleen, which revealed no bacterial burden and the infiltration of inflammatory immune cells in the kidneys of antibody-injected mice (Fig. 7E ). When we injected antibodies 2 h after S. aureus MW2 infection, we obtained similar results even though the effect of antibody injection was milder ( Supplementary Fig. S2 ). The final survival of the mice with delayed antibody injection was about 20% lower than the simultaneous injection group. Taken together, the results demonstrate that CpG-DNA-induced antibodies led to increased survival and enhanced bacterial clearance in S. aureus MW2-infected mice.
Discussion
Bacterial DNA and synthetic oligonucleotides with CpG dinucleotide motifs (CpG-DNA) have diverse immunomodulatory effects. Further, the administration of CpG-DNA in in vitro and in vivo model systems has revealed protective effects against various bacterial species, including MRSA. In this study, we focused on the induction of bacteria-reactive antibodies following the administration of CpG-DNA and the underlying functional mechanisms of the antibodies against S. aureus infection. CpG-DNA triggered the production of bacteria-reactive antibodies in the peritoneal cavity, which significantly increased the survival of mice after S. aureus infection by enhancing phagocytosis. CpG-DNA activates immune cells such as macrophages, dendritic cells, NK cells, and B lymphocytes 1,3,4,7 . CpG-DNA upregulates the expression of cytokines, chemokines, major histocompatibility (MHC) class II molecules, and costimulatory molecules in various immune cells [4] [5] [6] [7] . Therefore, CpG-DNA are considered as potentially useful immune adjuvants 1,2,6 . Administering CpG-DNA to animals can enhance host immunity against intracellular and extracellular pathogens 15, 16 . Here, we confirmed that the administration of CpG-DNA improved survival rates and enhanced bacterial clearance in tissues after S. aureus infection (Fig. 1) . Several reports suggest that CpG-DNA pre-treatment within 72 h before infection induces cytokine expression, including IL-6, IL-12, IFN-γ, and TNF-α, which contribute to host defense 5, 16, 29 . However, the effects of cytokine expression might have been minimized in our study as we administered CpG-DNA 7 days before S. aureus infection. Therefore, we hypothesized that another mechanism was involved in the observed antibacterial effects of CpG-DNA.
CpG-DNA can trigger host immunity through phagocytosis 19, 30 . An analysis of the cell populations in the mouse peritoneal cells revealed high percentages of myeloid cells in the peritoneal cavity of normal mice ( Fig. 2A) . Therefore, we speculated that many types of myeloid cells, such as macrophages, dendritic cells, and neutrophils, might be activated by CpG-DNA in the peritoneal cavity and promptly participate in the phagocytosis of the bacteria. Several studies have reported bacterial infections that were induced by the intranasal (i.n.), i.v., or i.p. injection of bacteria 9, 26, 29 . In particular, one study noted that almost 5 × 10 8 CFU of S. aureus were needed to perform survival experiments in mice following i.p. infection 26 . Interestingly, this concentration of S. aureus is approximately 40-50 times higher than the concentration used for i.v. infection in this study, which supports the essential role of peritoneal cells in bacterial removal.
Two days after i.v. S. aureus infection, the number of lymphoid and myeloid cells was drastically decreased and the ratios of immune cells were altered in the peritoneal cavity, spleen, and bone marrow. The change in the cell populations was especially prominent in the peritoneal cavity. B2 and T cells, known as adaptive immune cells, were virtually nonexistent in mice infected with S. aureus without CpG-DNA pre-treatment. However, B2 and T cell populations were largely maintained in the mice pre-treated with CpG-DNA prior to S. aureus infection ( Fig. 2A) . Therefore, these data suggest that the preservation of immune cell populations is the first line of CpG-DNA-mediated antibacterial effects. Nonetheless, the mechanism underlying this observation remains unclear. Because the amount of total antibodies increased following CpG-DNA treatment (Fig. 3) , we believe that CpG-DNA triggered the differentiation and expansion of some B cells, which then secreted antibodies, contributing to the antibacterial activity.
It has been reported that natural antibodies have antibacterial activity 31 . More specifically, it was suggested that some natural antibodies in normal serum, called polyreactive antibodies, have broad antibacterial activity and prevent the infection of several bacteria 32 . These bacteria-reactive antibodies have moderate binding affinity to a variety of antigens. Here, we confirmed that antibodies with broad reactivity against bacteria exist in the murine peritoneal cavity and serum in the absence of bacterial stimulation. In addition, we found that the amount of bacteria-reactive antibodies was markedly increased by the administration of CpG-DNA, especially in the peritoneal cavity ( Fig. 3) . Furthermore, the bacteria-reactive antibody levels were significantly increased when we isolated peritoneal B cells and stimulated them with CpG-DNA ( Fig. 4) . Therefore, we propose that Scientific REPORTs | (2018) 8:16236 | DOI:10.1038/s41598-018-34722-y peritoneal B cells might be the primary targets of CpG-DNA in our system, and that antibody production can be induced in a T cell-independent manner. Considering that serological memory can be maintained by polyclonal activation of human memory B cells 33 , it is one possibility that stimulation of TLR9 with CpG-DNA results in the proliferation of existing memory B cells. Previously, it was suggested that B1 cells predominantly reside in the peritoneal cavity and produce polyreactive antibodies in response to microbial antigens 34, 35 . Therefore, we investigated whether CpG-DNA had a differential effect on the production of bacteria-reactive antibodies by B1 and B2 cells in the peritoneal cavity and found that both B cell types produced bacteria-reactive antibodies in response to CpG-DNA, although B1 cells generally produced higher antibody amounts than B2 cells. When we repeated the CpG-DNA injections in mice, the amount of total IgG and bacteria-reactive IgG was increased (data not shown). However, no enhanced effect was observed in vitro ( Fig. 4) . Therefore, it is likely that cellular or molecular factors other than B cells are involved in the enhanced effects of CpG-DNA observed in vivo. The bacteria-reactive antibodies isolated from the peritoneal cavity of normal mice and CpG-DNA-treated mice enhanced phagocytosis in RAW 264.7 cells, with higher activity apparent with the antibodies from the CpG-DNA-treated mice (Fig. 5 ). When we examined the direct effects of normal IgG and the 3F5H6 mIgG bacteria-reactive monoclonal antibody isolated from CpG-DNA-stimulated peritoneal B cells, we found that the phagocytic activity of RAW264.7 cells and primary peritoneal cells were enhanced by the antibodies (Fig. 6) . Further, the phagocytic activity of the cells was more effectively enhanced by 3F5H6 mIgG than normal IgG. As well, the injection of antibodies enhanced survival and bacterial clearance in several tissues in the S. aureus-infected mice, and 3F5H6 mIgG was much more effective than normal IgG (Fig. 7) . Therefore, we suggest that CpG-DNA stimulates the production of bacteria-reactive antibodies, which, in turn, contribute to the defense against bacterial infection through mechanisms including enhanced phagocytosis, as previously suggested 32, 36 . Because 3F5H6 mIgG exhibited superior effects compared to normal IgG, 3F5H6 mIgG might be a promising therapeutic for the treatment of bacterial infections.
The protective effects of CpG-DNA-induced antibodies following S. aureus infection was confirmed, but bacterial clearance was more evident in the kidney from CpG-DNA-injected mice than in those from antibody-injected mice ( Figs 1C,D and 7C,D) . A detailed investigation of antibody-injected mice that survived for 30 days after S. aureus infection revealed that the mice had no bacterial burden in the kidney and a greater number of immune cells in the kidney compared to PBS-injected mice, suggesting the efficient infiltration of inflammatory cells (Fig. 7E) . Therefore, we believe that CpG-DNA could activate many factors, such as cytokines and other cellular mechanisms, in addition to the production of bacteria-reactive antibodies, and that together these factors might cause more efficacious immunomodulatory effects following bacterial infection. Although we focused on IgG in this study, natural polyreactive antibodies are mainly IgM 37 . IgM antibodies have lower affinity than IgG, but have advantages such as high avidity and broad specificity. Therefore, stimulation with CpG-DNA can activate more efficiently than the injection of IgG alone. Taken together, it is likely that CpG-DNA activates innate immunity and alerts the immune system, which then promotes a more efficient response. Some reports insist that a combined treatment with antibodies and antibiotics is more effective against MRSA bacteremia than one type of treatment 23, 24 . In this context, combined therapies involving various combinations of antibodies, adjuvants, and antibiotics, could be considered.
In conclusion, we demonstrated that bacteria-reactive antibodies induced by CpG-DNA administration exhibit protective functions against S. aureus infection in murine models, and that the antibodies enhanced phagocytic efficiency. Although passive immunization has been the recent focus of numerous investigations, no antibodies have been approved for clinical use. Therefore, future studies should focus on the development of a humanized antibody to resist MRSA infection, which might also be useful in the treatment of infectious diseases. . Mice were anesthetized under isoflurane (3% to 5% for induction and 1% to 3% for maintenance, JW Pharmaceutical, Seoul, Korea) inhalation to minimize pain. After the experiments were completed, the mice were sacrificed by CO 2 inhalation and all efforts were made to minimize suffering.
Methods
CpG-DNA. CpG-DNA 1826 and non-CpG-DNA 2041 were purchased from GenoTech (Daejeon, Korea).
The backbones of the sequences were modified with phosphorothioate. The following oligodeoxynucleotide sequences were used: CpG-DNA 1826, 5′-TCCATGACGTTCCTGACGTT-3′ and non-CpG-DNA 2041, 5′-CTGGTCTTTCTGGTTTTTTTCTGG-3′. The non-CpG-DNA 2041 was used as a negative control. Oligodeoxynucleotides were dissolved in distilled water.
Bacteria culture and in vivo infection studies. Staphylococcus aureus (S. aureus, KCCM 12103),
Staphylococcus epidermidis (S. epidermidis, KCCM 40416), and Streptococcus pyogenes (S. pyogenes, KCCM 11873) were purchased from the Korean Culture Center of Microorganisms (KCCM, Seoul, Korea). The S. aureus Δspa mutant (M0107) was used. Strain M0107 is an IgG-binding protein A-deficient Δspa mutant of RN4220 38 . All bacteria were grown at 37 °C in Lysogeny broth (LB). S. aureus strain MW2 (MRSA) was grown at 37 °C in Columbia broth supplemented with 2% NaCl 39 . All bacteria were grown overnight, re-cultured in fresh media at a 1/50 dilution until the mid-log phase (OD 600 0.5-0.6), and harvested. S. aureus MW2 was washed with PBS, centrifuged, and diluted to 5 × 10 7 colony forming units (CFU)/mL in PBS. BABL/c mice were injected with PBS or 50 μg of CpG-DNA 1826 intraperitoneally (i.p.). After 7 days, the mice were injected i.v. with 0.2 ml of PBS or the bacterial suspension. Following infection, the mice were observed for morbidity or recovery for 7 days. We investigated the survival rate as well as the histopathology, bacterial loads (CFU), and immune cell populations in the control and infected mouse tissues, and measured antibody levels in the peritoneal fluid and serum from the control and infected mice.
